• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
EMD
Click for more information
0.00% 5.1¢

EMYRIA LIMITED - News & Media

Market Cap $18.69M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Emyria Limited is an Australia-based clinical services and drug development company. The... Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.More

Articles & Videos

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair has funded the company $0.3M on Tuesday.

23 Apr 2024 12:42 (AEST)

Emyria launches Empax Centre - pioneering innovation in mental health treatment

Emyria Limited has opened the Empax Centre, a cutting-edge facility designed to advance innovative mental health treatments, including psychedelic-assisted therapies.

10 Apr 2024 12:13 (AEST)

Emyria hits milestone in PTSD treatment with first female specialist for MDMA therapy

Emyria has nominated its first female psychiatrist to treat post-traumatic stress disorder using the drug ecstasy.

05 Apr 2024 09:58 (AEDT)

Emyria partners with 'Reach Wellness' to support PTSD patients

Emyria has partnered with charity group 'Reach Wellness' to research the effectiveness of using MDMA to assist PTSD patients.

03 Apr 2024 14:11 (AEDT)

Emyria (ASX:EMD) recruits first patient in MDMA-assisted therapy trial for PTSD

Emyria (ASX:EMD) has recruited the first patient in its phase 2B MDMA-assisted therapy trial for post-traumatic stress disorder (PTSD).

10 Jul 2023 12:47 (AEST)

Emyria (ASX:EMD) to acquire leading psychological trauma care service Pax Centre

Emyria (ASX:EMD) has announced a strategic acquisition of the Pax Centre, enhancing its patient-centric clinical service portfolio.

03 Jul 2023 14:31 (AEST)

Emyria (ASX:EMD) unveils highest-potency CBD capsule

Emyria (ASX:EMD) has introduced its highest-potency ultra-pure CBD capsule to its cannabinoid medicine pipeline.

24 Apr 2023 17:48 (AEST)

Emyria (ASX:EMD) strikes EMD-RX5 commercialisation deal with Aspen Australia

Emyria (ASX:EMD) has entered an agreement with Aspen Australia for the licensing and commercialisation of EMD-RX5.

04 Apr 2023 11:54 (AEST)

Emyria (ASX:EMD) reveals "strong recruitment" for EMD-RX5 phase IIItrial

Emyria (ASX:EMD) has announced "strong recruitment" from its ongoing phase three clinical trial to facilitate its EMD-RX5 product in becoming an over-the-counter medicine.

23 Mar 2023 12:12 (AEDT)

Drugs in unexpected places: How Emyria (ASX:EMD) is looking to treat PTSD and Parkinson's with MDMA

Emyria (EMD) and the University of Western Australia are at the forefront of treating mental health and neurological disease through their pre-clinical study of MDMA.

22 Mar 2023 06:02 (AEDT)



(20min delay)
Last
5.1¢ 		Change
0.000(0.00%) 		Mkt cap ! $18.69M
Open High Low Value Volume
5.0¢ 5.1¢ 4.9¢ $17.76K 359.9K

Buyers (Bids)

No. Vol. Price($)
1 204081 4.9¢
 

Sellers (Offers)

Price($) Vol. No.
5.1¢ 42827 2
View Market Depth
Last trade - 15.59pm 06/05/2024 (20 minute delay) ?
Last
4.9¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
5.0¢ 5.0¢ 4.9¢ 39731
Last updated 12.36pm 06/05/2024 ?
EMD (ASX) Chart

Top Stories

Tamboran is listing on the NYSE, and Wall Street is paying attention

If you needed evidence that Tamboran Resources is bullish on the NT's Beetaloo Basin, look no further than its decision to list on the NYSE.
Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy Westpac Banking Corporation has reported a 16 percent drop in net profit (to $3.342 billion) for the first half of the 2024 financial year compared to the same time last year.
Sold out signs go up for RIU Resources Roundup in Sydney More than 115 companies will be participating in this year's RIU Resources Roundup in Sydney.
Maiden drilling at West Arunta hints at major IOCG system for Rincon Rincon Resources believes that drill core picked up from a maiden program of work at its West Arunta project in Western Australia indicates potential for a major iron oxide copper gold deposit.
Mantle Minerals to kick off drilling at Mt Berghaus in WA Mantle Minerals (ASX:MTL) has announced it's kicking off a 122-hole drill run on-site its Mt Berghaus acreage in Western Australia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.